Wednesday, July 8, 2026

Patent intelligence · US

US 12031130

Composition for modifying target gene

granted A61KA61K31/7105A61K38/465A61K47/24
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 18
Applicant portfolio 1,436
Patent details — US 12031130
Jurisdiction
US
Status
granted
Grant date
Jul 9, 2024
Expiration
Jul 4, 2044
Claims
27
CPC classes
A61K, A61K31/7105, A61K38/465, A61K47/24
View on Google Patents ↗

Quick answer

US 12031130 (Composition for modifying target gene) is held by Takeda Pharmaceutical Company Limited. Status: granted. Granted Jul 9, 2024. Expires Jul 4, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
27
CPC classes
A61K, A61K31/7105, A61K38/465, A61K47/24, A61K9/0019, A61K9/5123

More from Takeda Pharmaceutical Company Limited

Related pharmaceutical patents in our USPTO index.

  1. US 12428403

    N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists

    Takeda Pharmaceutical Company Limited · Expires Sep 25, 2045

    granted
  2. US 12421188

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Expires Sep 18, 2045

    granted
  3. US 12419890

    Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors

    Takeda Pharmaceutical Company Limited · Expires Sep 18, 2045

    granted
  4. US 12415866

    Monoclonal antibody inhibitor of Factor XIIa

    Takeda Pharmaceutical Company Limited · Expires Sep 11, 2045

    granted
  5. US 12415782

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Expires Sep 11, 2045

    granted
  6. US 12409210

    CNS delivery of therapeutic agents

    Takeda Pharmaceutical Company Limited · Expires Sep 4, 2045

    granted
  7. US 12404237

    Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives

    Takeda Pharmaceutical Company Limited · Expires Aug 28, 2045

    granted
  8. US 12403154

    Administration of sting agonist and checkpoint inhibitors

    Takeda Pharmaceutical Company Limited · Expires Aug 28, 2045

    granted

Frequently asked questions

What is US patent 12031130?

US 12031130 (Composition for modifying target gene) is held by Takeda Pharmaceutical Company Limited. Status: granted. Granted Jul 9, 2024. Expires Jul 4, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12031130?

Takeda Pharmaceutical Company Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1,436 pharmaceutical patents for this assignee.

When does US 12031130 expire?

Our index shows an expiration date of Jul 4, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.